Stay updated with breaking news from Primary Biliary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results from the phase 3 trial showed seladelpar elicited biochemical response, normalized alkaline phosphatase, and reduced pruritus at a greater rate than placebo.
Phase 1 trial initiated to assess safety/tolerability and absolute bioavailability of TH104 with topline data expected in 2Q24Planning well underway for Phase 2 of TH104 in primary biliary cholangitis (PBC) patients suffering from moderate-to-severe chronic pruritusCompany outlines near-clinical pipeline of novel an...
This article focuses on cholangiocyte biology and incidence of cholangiopathies.1
March 7, 1960-Jan. 15 2024 NEW ULM—Bradley B. Zollner, age 63, of New Ulm died Monday, January 15, 2024, at the University of Minnesota Medical Center in Mi
The post-hoc analysis of the phase 3 ENHANCE study provides the first published evidence of a correlation between decreases in IL-31, bile acids, and pruritus symptoms in PBC following treatment with an investigational agent.